Fig. 2: Effect of SMARCB1 on BLCA tumor growth and metastasis.
From: The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer
A Validation of CRISPR/Cas9 based SMARCB1 KO (clone 16) and rescue (ectopic overexpression of SMARCB1 in KO derived from clone 16) by immunoblot analysis in the T24 BLCA cell line. GAPDH was used as loading control. B Representative bioluminescence images (BLI) of mice bearing T24 Control (ctrl), SMARCB1 KO, and SMARCB1 rescue orthotopic xenografts on day 15. C Weight of orthotopic mice bladders harboring tumors (endpoint, day 23) from T24 ctrl (n = 9), SMARCB1 KO (n = 7), and SMARCB1 rescue (n = 9) [Data are represented as mean ± standard deviation (SD)]. D Representative ex-vivo BLI images of metastatic lesions (lungs, liver, kidneys, and stomach & intestine) from mice bearing T24 ctrl, SMARCB1 KO, and rescue orthotopic xenografts. [Note: Representative ex-vivo BLI images were cropped from different non overlapping regions of same images for lungs, liver, kidneys, and stomach & intestine]. E Scatter plots represent the quantification of BLI signal of lungs, liver, kidneys, and stomach & intestine of mice bearing orthotopic xenografts from T24 ctrl (n = 9), SMARCB1 KO (n = 7) and rescue (n = 9) (quantified by BLI signal; photons/sec/cm2/sr) [Data are represented as mean ± standard deviation (SD)]. F Histology images of Hematoxylin and eosin (H&E) staining of ex-vivo metastatic organs derived from SMARCB1 KO metastatic lesions derived from panel (D). The metastatic lesions were highlighted with dotted boxes. Scale bar represents 100 µm. For panels C and E, P-values were determined by unpaired two-tailed Student’s t-test. Source data are provided as a Source Data file.
